– TG4050 (myvac®): First positive results from the two Phase I trials. Additional data to be presented at AACR 2022 in April.
– TG4001: First patient enrolled in Phase II study in June 2021. Active patient recruitment in Europe and trial initiation in the US. Interim analysis expected in Q4 2022.
– BT-001 (Invir.IO™): IND approval for Phase I/IIa trial in the US, ongoing enrollment in Europe. Next clinical update in Q2 2022.
– TG6002: Clinical proof-of-concept of the intravenous administration of an oncolytic virus presented at major congresses in 2021. End of Phase I expected in mid-2022.
– AstraZeneca collaboration (Invir.IO™): First option license for an oncolytic virus exercised in 2021. R&D collaboration to develop additional candidates ongoing.
– €49.6 million cash available at year-end 2021 providing financial visibility until end of 2023.
Conference call in English scheduled today at 6:00 p.m. CET (details at the end of the release)
STRASBOURG, France–(BUSINESS WIRE)–Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2021 and provides an update on its product pipeline.
Hedi Ben Brahim, CEO of Transgene commented: “It has been more than a year since I joined Transgene as Chairman and Chief Executive Officer and I am pleased and proud to have experienced and delivered such a successful year for the Company.
Transgene achieved several important milestones in 2021. We announced the first positive data from two Phase I trials with TG4050, our individualized therapeutic vaccine based on our myvac® platform. These results demonstrated the immunogenicity of the vaccine, which led to the first signs of clinical activity. We expect to confirm these results in the coming months and to provide more in-depth data at major scientific congresses in 2022.
The Phase II trial with TG4001, our therapeutic vaccine against HPV16-positive anogenital cancers, was launched in 2021, with the first patient enrolled in June; recruitment is continuing at a steady pace. First data from an interim analysis, including up to 50 patients, is anticipated in the fourth quarter of 2022.
We also made significant progress with our oncolytic virus pipeline. We recruited the first patient into the Phase I/IIa study evaluating BT-001, our first candidate from our Invir.IO™ platform. We also presented the first Phase I data with TG6002 at two major conferences in 2021: AACR and ESMO. These results confirm the feasibility of intravenous administration of this oncolytic virus. The ability to be given intravenously would considerably extend the use of our Invir.IO™ based virus therapies in oncology, significantly expanding the market opportunity they can address.
In addition, our expertise and the clear benefits that our Invir.IO™ platform can deliver was recognized with the first license option exercised by AstraZeneca for an oncolytic virus in late 2021. This exercise results in an upfront payment of $8 million. The collaboration with AstraZeneca continues under the agreement for the development of other oncolytic immunotherapies by Transgene.
Following the successful completion of a €34.1 million private placement in June 2021 and the additional sale of Tasly BioPharmaceuticals shares in September 2021 for €17.4 million, Transgene has financial visibility until the end of 2023. This puts us in strong position to pursue Transgene’s mission: create value by developing new innovative cancer therapies.”
PRELIMINARY POSITIVE RESULTS WITH TG4050 CONFIRMING ITS POTENTIAL AND REINFORCING TRANSGENE’S POSITION AS A GLOBAL LEADER IN THE FIELD OF INDIVIDUALIZED THERAPEUTIC CANCER VACCINES
Transgene is developing TG4050, an individualized immunotherapy against cancer based on its highly innovative myvac® platform. This platform delivers a customized approach, by combining Transgene’s expertise in viral engineering with NEC’s artificial intelligence capabilities. TG4050 is currently being assessed in two Phase I clinical trials in Europe and in the US (in ovarian and HPV-negative head and neck cancers); NEC is financing 50% of these studies. The product is manufactured by Transgene in an in-house GMP production unit in Strasbourg. The first results were announced in November 2021.
Positive data were generated in the first six patients treated and demonstrate the strong potential of TG4050. The specific immune responses observed show a robust T-cell response against multiple targeted mutations (neoantigens), with a median of 10 positive responses per patient. The development of adaptive responses also suggest that the vaccine is able to effectively prime the immune system. The studies also provide preliminary data on the clinical activity of this individualized immunotherapy. Four patients were treated in the ovarian cancer study, including one patient with a CA-125 elevation which was cleared by vaccination for nine months before death from an unrelated chronic disease, and one patient who remained stable for nine months after the appearance of radiological lesions and initiation of treatment. In the head and neck cancer study, patients treated for 10 and 5 months, respectively, were stable and disease-free as of November 22, 2021. More details are available here.
These data reinforce the rationale for TG4050’s prediction system and support the validation of the myvac® platform as an efficient approach for anti-tumor vaccination. Additional data will be presented at the AACR annual meeting on April 12, 2022, and at other scientific conferences in 2022.
ONGOING ENROLLMENT IN THE RANDOMIZED PHASE II STUDY WITH TG4001 IN HPV16-POSITIVE ANOGENITAL CANCERS
TG4001 is a therapeutic vaccine targeting HPV-positive tumors, and is engineered to express HPV16 E6 and E7 antigens and interleukin 2 (IL-2) which stimulates immune responses. TG4001 is being developed to target recurrent or metastatic HPV-16 positive cancers, without liver metastasis, based on a clinical benefit observed in the Phase Ib/II trial. TG4001 is currently being evaluated in a randomized Phase II trial of up to 150 patients comparing the efficacy of the combination of TG4001 with avelumab versus avelumab alone. The first patient was enrolled in June 2021. The trial is actively enrolling patients in Europe (France and Spain) and has recently been initiated in the US.
An interim analysis will be performed after the inclusion of approximately 50 patients. Transgene expects to report the results of this analysis in the fourth quarter of 2022.
BT-001, FIRST ONCOLYTIC VIRUS BASED ON INVIR.IO™ PLATFORM, CONTINUES ITS CLINICAL DEVELOPMENT IN EUROPE AND IN THE US
BT-001 is a patented VVcopTK–RR– oncolytic virus, with high antitumor potential, based on the Invir.IO™ platform. It is being co-developed with BioInvent. It has been engineered to express both a human recombinant anti-CTLA-4 antibody and the human GM-CSF cytokine locally in the tumor, aiming at inducing a local Treg depletion, and providing significant therapeutic activity by limiting systemic exposure.
Promising preclinical results with BT-001 were presented at the SITC 2021 annual meetings. They demonstrated high and robust intratumoral antitumor activity, resulting in tumor disappearance in in vivo models. In January 2022, preclinical proof-of-concept data were published in the Journal for ImmunoTherapy of Cancer (JITC). The published results demonstrated the potential of the virus to provide therapeutic benefit beyond current anti-PD1/anti-CTLA-4 immune checkpoint inhibitors. The article can be downloaded here.
Further preclinical data will be presented at the AACR on April 12, 2022.
A multicenter, open-label Phase I/IIa study is evaluating ascending doses of BT-001 alone and in combination with pembrolizumab. The first patient in this trial, approved in Europe (France and Belgium) and in the US, was enrolled in February 2021. Patient recruitment is progressing as expected.
The next clinical update on the ongoing Phase I trial is expected in the second quarter of 2022.
TG6002 PROVIDES THE CLINICAL PROOF-OF-CONCEPT OF THE INTRAVENOUS ADMINISTRATION OF TRANSGENE’S ONCOLYTIC VIRUSES
TG6002 is based on Transgene’s patented VVcopTK–RR– strain, it has been engineered to express a chemotherapeutic agent (5-FU) directly in the tumor. TG6002 is being assessed in two Phase I/II clinical trials in gastrointestinal cancers, for which 5-FU is a common treatment. Its administration is evaluated by the intravenous and intrahepatic artery routes.
Initial Phase I data were presented at AACR 2021 and ESMO 2021. The Phase I data provide the clinical proof-of-concept of the feasibility of the intravenous (IV) administration of Transgene’s patented oncolytic virus backbone. The data showed that, after IV administration, TG6002 is able to selectively replicate and persist in tumor cells leading to the local expression of its functional payload (the FCU1 gene).
This finding supports the potential of IV administration of oncolytic virus based on the VVcopTK–RR– strain behind the Invir.IO™ platform, extending the use of Transgene’s oncolytic therapies to a broad range of solid tumors.
The Phase I trial evaluating TG6002 administered intravenously is expected to be completed by mid-2022. Comprehensive translational data will be presented in the fourth quarter of 2022.
SUMMARY OF ONGOING CLINICAL TRIALS
|
myvac®
TG4050 Phase I NCT03839524 |
Targets: tumor neoantigens
Ovarian cancer – after surgery and first-line chemotherapy
> Additional data expected in 2022, including at the AACR |
|
TG4050 Phase I NCT04183166 |
HPV-negative head and neck cancer – after surgery and adjuvant therapy
> Additional data expected in 2022, including at the AACR |
|
TG4001
+ avelumab NCT03260023 |
Targets: HPV16 E6 and E7 oncoproteins Recurrent/metastatic anogenital HPV-positive – 1st (patients ineligible for chemotherapy) and 2nd line
> Results of the interim analysis expected in Q4 2022 (N≈50) |
|
Invir.IO™ BT-001 Phase I/IIa
NCT04725331 |
Payload: anti-CTLA4 antibody and GM-CSF cytokine Solid tumors
> Next clinical update expected in Q2 2022 |
|
TG6002 Phase I/IIa NCT03724071 |
Payload: FCU1 for the local production of a 5-FU chemotherapy Gastro-intestinal cancer (colorectal cancer for Phase II) – Intravenous (IV) administration
> End of Phase I expected mid-2022 |
|
TG6002 Phase I/IIa NCT04194034 |
Colorectal cancer with liver metastasis – Intrahepatic artery (IHA) administration
> First data expected mid-2022 |
ASTRAZENECA COLLABORATION : NEW MILESTONE
WITH THE FIRST LICENSE OPTION EXERCISE
AstraZeneca has exercised a first license option in December 2021 for an oncolytic virus from Transgene’s Invir.IO™ platform. Transgene received an $8 million payment for the exercise of this option and is also eligible to receive development, regulatory and sales-based milestones payments as well as a royalty based on future commercial sales.
The collaboration with AstraZeneca, which includes co-development of other potential oncolytic immunotherapies, is ongoing. AstraZeneca has an option to acquire the rights to each of these innovative drug candidates for further clinical development.
A NEW COLLABORATION WITH INVIR.IO™ PLATFORM
In January 2022, Transgene announced the launch of a preclinical collaboration with PersonGen BioTherapeutics. This collaboration aims to evaluate the feasibility and efficacy of a combination therapy against solid tumors, combining PersonGen’s CAR T cell injection with an oncolytic virus from the Invir.IO™ platform.
APPOINTMENT OF STEVEN BLOOM
AS CHIEF BUSINESS OFFICER
Steven Bloom joined Transgene as Vice President, Chief Business Officer (CBO) in February 2022. He joined Transgene’s executive committee to lead global business development strategy, alliance management and program management of the Company, with a focus on building a strong visibility in the US as part of establishing Transgene as a world leader in virus-based immunotherapies.
KEY FINANCIALS FOR 2021
– Operating income of €17.4 million in 2021, compared to €9.9 million in 2020.
R&D services for third parties amounted to €10.0 million in 2021 (€3.0 million in 2020), mainly due to the collaboration with AstraZeneca which generated €9.9 million in revenues in 2021 (€2.9 million in 2020). This increase is related to the first license option exercised by AstraZeneca in 2021 for €7.1 million, for an oncolytic virus developed by Transgene.
Research tax credit amounted to €7.0 million in 2021 (€6.3 million in 2020).
– Net operating expenses of €40.9 million in 2021, compared to €33.9 million in 2020.
R&D expenses were €32.9 million in 2021 (€27.3 million in 2020). This increase is mainly due to the acceleration of clinical trials in 2021 and the start of a new process development project.
General and administrative expenses amounted to €7.4 million in 2021 (€6.5 million in 2020).
– Financial income of €4.0 million in 2021, compared to €6.8 million in 2020.
The partial sale of the Tasly BioPharmaceuticals shares in September 2021 generated a net gain on asset disposal of €1.3 million. Transgene’s remaining shareholding was revaluated and resulted in financial income of €2.4 million in 2021. This figure corresponds to the difference between the last market price compared with last year.
– Net loss of €19.5 million in 2021, compared to a net loss of €17.2 million in 2020.
– Net cash burn of €10.0 million in 2021 (excluding capital increase), compared to €17.0 million in 2020.
– Cash available at year-end 2021: €49.6 million, compared to €26.3 million at the end of 2020, following the completion of a €34.1 million private placement in June 2021. In addition, Transgene still holds Tasly BioPharmaceuticals shares valued at €18.9 million at the end of December 2021.
– Transgene has a financial visibility until the end of 2023.
The financial statements for 2021 as well as management’s discussion and analysis are attached to this press release (Appendices A and B).
The Board of Directors of Transgene met on March 16, 2022, under the chairmanship of Hedi Ben Brahim and closed the 2021 financial statements. Audit procedures have been performed by the statutory auditors and the delivery of the auditors’ report is ongoing.
The Company’s universal registration document, which includes the annual financial report, will be available early April 2022 on Transgene’s website, www.transgene.fr.
A conference call in English is scheduled today on March 16, 2022, at 6:00 p.m. CET (12:00 p.m. ET).
Webcast link to English language conference call:
https://channel.royalcast.com/landingpage/transgene/20220316_1/
Participant telephone numbers:
|
France: +33 (0) 1 7037 7166 United Kingdom (international): +44 (0) 33 0551 0200
|
Confirmation code: Transgene |
A replay of the call will be available on the Transgene website (www.transgene.fr) following the live event.
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at: www.transgene.fr.
Follow us on Twitter: @TransgeneSA
Transgene disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Appendix A: Financial statements 2021
CONSOLIDATED BALANCE SHEET, IFRS
(in € thousands)
|
Assets |
December 31,2021 |
December 31,2020 |
|
CURRENT ASSETS |
|
|
|
Cash and cash equivalents |
5,911 |
5,277 |
|
Other current financial assets |
43,658 |
21,077 |
|
Cash, cash equivalents and other current financial assets |
49,569 |
26,354 |
|
Trade receivables |
10,133 |
1,667 |
|
Other current assets |
2,543 |
2,666 |
|
Total current assets |
62,245 |
30,687 |
|
NON-CURRENT ASSETS |
|
|
|
Property, plant and equipment |
11,295 |
13,110 |
|
Intangible assets |
92 |
141 |
|
Non-current financial assets |
20,772 |
34,042 |
|
Other non-current assets |
7,434 |
7,473 |
|
Total non-current assets |
39,593 |
54,766 |
|
Total ASSETS |
101,838 |
85,453 |
|
Liabilities and equity |
December 31,2021 |
December 31,2020 |
|
CURRENT LIABILITIES |
|
|
|
Trade payables |
7,692 |
5,066 |
|
Current financial liabilities |
1,395 |
1,426 |
|
Provisions for risks and expenses |
48 |
511 |
|
Other current liabilities |
5,454 |
6,626 |
|
Total current liabilities |
14,589 |
13,629 |
|
NON-CURRENT LIABILITIES |
|
|
|
Non-current financial liabilities |
15,241 |
16,938 |
|
Employee benefits |
3,958 |
4,060 |
|
Other non-current liabilities |
841 |
110 |
|
Total non-current liabilities |
20,040 |
21,108 |
|
Total liabilities |
34,629 |
34,737 |
|
EQUITY |
|
|
|
Share capital |
48,886 |
41,921 |
|
Share premiums and reserves |
70,374 |
40,938 |
|
Retained earnings |
(31,092) |
(13,861) |
|
Profit/(loss) for the period |
(19,536) |
(17,231) |
|
Other comprehensive income/(loss) |
(1,423) |
(1,051) |
|
Total equity attributable to Company shareholders |
67,209 |
50,716 |
|
TOTAL LIABILITIES AND EQUITY |
101,838 |
85,453 |
Consolidated income statement, IFRS
(in € thousands, except for per-share data)
|
|
December 31,2021 |
December 31,2020 |
|
Revenue from collaborative and licensing agreements |
9,993 |
2,981 |
|
Government financing for research expenditure |
7,021 |
6,362 |
|
Other income |
399 |
572 |
|
Operating income |
17,413 |
9,915 |
|
Research and development expenses |
(32,883) |
(27,346) |
|
General and administrative expenses |
(7,369) |
(6,547) |
|
Other expenses |
(686) |
(15) |
|
Operating expenses |
(40,938) |
(33,908) |
|
Operating income/(loss) |
(23,525) |
(23,993) |
|
Financial income/(loss) |
3,989 |
6,762 |
|
Income/(loss) before tax |
(19,536) |
(17,231) |
|
Income tax expense |
– |
– |
|
NET INCOME/(LOSS) |
(19,536) |
(17,231) |
|
Basic earnings per share (€) |
(0.21) |
(0.21) |
|
Diluted earnings per share (€) |
(0.20) |
(0.21) |
Cash Flow statement, IFRS
(in € thousands)
|
|
December 31,2021 |
December 31,2020 |
|
Cash flow from operating activities |
|
|
|
Net income/(loss) |
(19,536) |
(17,231) |
|
Cancellation of financial income/(loss) |
(3,989) |
(6,762) |
|
Elimination of non-cash items |
|
|
|
Provisions |
(1,031) |
722 |
|
Depreciation and amortization |
2,521 |
1,786 |
|
Share-based payments |
3,002 |
1,744 |
|
Others |
(112) |
(320) |
|
Net cash generated from/(used in) operating activities before change in working capital and other operating cash flow |
(19,145) |
(20,061) |
|
Change in operating working capital requirements |
|
|
|
Current receivables and prepaid expenses |
(7,745) |
897 |
|
Research tax credit (RTC) |
(7,027) |
(6,352) |
|
Other current assets |
(242) |
717 |
|
Trade payables |
2,657 |
(2,057) |
|
Prepaid income |
(1,124) |
(2,015) |
|
Other current liabilities |
683 |
129 |
|
Net cash used in operating activities |
(31,943) |
(28,742) |
|
Cash flows from investing activities |
|
|
|
(Acquisitions)/disposals of property, plant and equipment |
(671) |
(811) |
|
(Acquisitions)/disposals of intangible assets |
(15) |
(41) |
|
(Acquisitions)/disposals of non-consolidated equity securities without significant influence |
17,193 |
18,224 |
|
Other (acquisitions)/disposals |
286 |
370 |
|
Net cash used in investing activities |
16,793 |
17,742 |
|
Cash flow from financing activities |
|
|
|
Net financial income/(loss) proceeds |
(167) |
(123) |
|
Gross proceeds from the issuance of shares |
34,129 |
– |
|
Share issue costs |
(787) |
– |
|
Conditional subsidies |
603 |
655 |
|
(Acquisitions)/disposals of other financial assets |
(22,582) |
21,041 |
|
Net amounts received for financing of tax credits |
6,050 |
6,288 |
|
Bank borrowing |
(197) |
(11,406) |
|
Financial leases and change in lease obligations |
(1,277) |
(1,514) |
|
Net cash generated from/(used in) financing activities |
15,772 |
14,941 |
|
Exchange rate differences on cash and cash equivalents |
12 |
(7) |
|
Net increase/(decrease) in cash and cash equivalents |
634 |
3,934 |
|
Cash and cash equivalents at beginning of period |
5,277 |
1,343 |
|
Cash and cash equivalents at end of period |
5,911 |
5,277 |
|
Investments in other current financial assets |
43,658 |
21,077 |
|
Cash, cash equivalent and other current financial assets |
49,569 |
26,354 |
Appendix B: Management Discussion of 2021 Financials
Operating income
Income from collaboration and licensing agreements represented €10.0 million in 2021 versus €3.
Contacts
Transgene:
Jean-Philippe Del
Chief Financial Officer
+33 (0)3 88 27 91 00
investorrelations@transgene.fr
Media: MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi
+44 (0)7714 306525
transgene@medistrava.com